ClinicalTrials.Veeva

Menu

Static Muscular Stretching for Treatment of PAD

Florida State University logo

Florida State University

Status

Completed

Conditions

Peripheral Artery Disease

Treatments

Device: Ankle Splint

Study type

Interventional

Funder types

Other

Identifiers

NCT04222751
19-005234 Mayo

Details and patient eligibility

About

Patients with peripheral arterial disease (PAD) often have walking impairment due to insufficient oxygen supply to skeletal muscle. The investigator's pilot study in PAD patients has shown that endothelial function and walking distance improve with regular static muscle stretching. Therefore, the purpose of this study is to determine whether prescriptive muscle stretching improves muscle oxygenation and walking ability in PAD patients. This is a single-blinded study in 40 patients with stable symptomatic PAD. Patients assigned to the stretch group will use ankle splints (both legs) to perform static muscle stretching for 4 weeks (ankle dorsiflexion applied 30 min/d, 5 days/wk). Patients assigned to the control group will also wear the ankle splints daily but without invoking any dorsiflexion, i.e., without stretching. Measurements will consist of ankle-brachial index (ABI) at rest and post-exercise, skeletal muscle oxygenation (evaluated with near-infrared spectroscopy (NIRS)), and 6 minute walk test (6MWT), performed at baseline and after 4 weeks of stretching (or control splint placement). In addition, NIRS will be used to evaluate muscle oxygenation while patients are wearing the splint device in order to quantitatively prescribe the angle of dorsiflexion that provides optimum stretch and deoxygenation of the calf muscles without causing pain. Primary outcomes include increased muscle oxygenation during exercise and walking distance after 4 weeks of static muscle stretching. Results from this study will be used to support funding applications for a larger efficacy trial.

Enrollment

21 patients

Sex

All

Ages

40 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age 40+
  • A resting ankle-brachial index (ABI) of 0.90 or less in either leg
  • Stable disease (PAD) for a minimum of 3-months

Exclusion criteria

  • Habitual exercise (30 minutes of continuous activity for 3 or more days per week)
  • Cardiovascular rehabilitation program during the past 3 months
  • Below or above-knee amputation, critical limb ischemia (ulceration or gangrene)
  • Leg pain at rest
  • Cardiorespiratory disease
  • Diabetes
  • Major surgery or lower extremity revascularization during the previous 3 months
  • Major medical illness treatment during the prior 12 months
  • Central neurological disease
  • Limited ankle or knee joint range of motion
  • Requirement of oxygen with activity or exercise
  • More than a class II New York Heart Association level of heart failure
  • Wheelchair confinement, or inability to walk
  • Cognitive disorder
  • Vasculitis problem including Takayasu's arteritis, Buerger's disease, collagen disease or Raynaud's disease

Trial design

Primary purpose

Basic Science

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

21 participants in 2 patient groups, including a placebo group

Stretch Group
Experimental group
Description:
Subjects assigned to this group will be instructed on how to wear the device to produce the appropriate amount of dorsiflexion (stretch). Splint devices will be worn at the assigned angle 5 days/week, 30 minutes/day, for 4 weeks. ABI, muscle oxygenation, and walking distance will be assessed pre/post stretching. Other health surveys will be administered.
Treatment:
Device: Ankle Splint
No Stretch Group
Placebo Comparator group
Description:
Subjects assigned to this group will wear the splints but instructed to wear the device in a position that produces no stretch. Splint devices will be worn at the assigned angle 5 days/week, 30 minutes/day, for 4 weeks. ABI, muscle oxygenation, and walking distance will be assessed pre/post stretching. Other health surveys will be administered.
Treatment:
Device: Ankle Splint

Trial contacts and locations

1

Loading...

Central trial contact

Mauricia Buchanan, RN; Albert Hakaim, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems